ST TSZY: Sodium Bicarbonate Injection passes the consistency evaluation of generic drugs
ST TSZY's wholly-owned subsidiary Hubei TSZY Pharmaceutical recently received approval from the National Medical Products Administration, with sodium bicarbonate injection passing the consistency evaluation for generic drugs. This medication is primarily used for the nonspecific treatment of metabolic acidosis, alkalinizing urine, and certain drug overdoses. This move will enhance the market competitiveness of the drug and accumulate experience for the consistency evaluation of generic drugs for the company's other products
According to the Zhitong Finance APP, ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiary Hubei Tian Sheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Tian Sheng") recently received the "Notice of Approval for Supplementary Drug Application" issued by the National Medical Products Administration, indicating that Hubei Tian Sheng's product "Sodium Bicarbonate Injection" has passed the consistency evaluation of generic drug quality and efficacy.
Clinically, Sodium Bicarbonate Injection is mainly used for: (1) treating metabolic acidosis; (2) alkalinizing urine; (3) intravenous infusion for non-specific treatment of certain drug overdoses. Sodium Bicarbonate Injection is included in the "National Essential Medicines List (2018)" and classified as a Category A product in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)."
The successful consistency evaluation of Hubei Tian Sheng's product "Sodium Bicarbonate Injection" is beneficial for enhancing the market competitiveness of this drug and also accumulates experience for the company's subsequent consistency evaluation work for other products
